KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Inventory Average (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Inventory Average for 15 consecutive years, with $181.1 million as the latest value for Q4 2025.

  • Quarterly Inventory Average rose 32.57% to $181.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181.1 million through Dec 2025, up 32.57% year-over-year, with the annual reading at $159.2 million for FY2025, 18.14% up from the prior year.
  • Inventory Average for Q4 2025 was $181.1 million at Halozyme Therapeutics, down from $183.7 million in the prior quarter.
  • The five-year high for Inventory Average was $183.7 million in Q3 2025, with the low at $50.8 million in Q1 2022.
  • Average Inventory Average over 5 years is $116.2 million, with a median of $124.1 million recorded in 2023.
  • The sharpest move saw Inventory Average decreased 14.63% in 2022, then soared 104.24% in 2023.
  • Over 5 years, Inventory Average stood at $54.9 million in 2021, then surged by 85.1% to $101.7 million in 2022, then increased by 26.12% to $128.3 million in 2023, then grew by 6.53% to $136.6 million in 2024, then surged by 32.57% to $181.1 million in 2025.
  • According to Business Quant data, Inventory Average over the past three periods came in at $181.1 million, $183.7 million, and $173.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.